...NEW YORK April 18 2012 /- Financial executives in the m...As part of the Health Care and Education Reconciliation Act of 2010...In the KPMG survey almost two-thirds (61 percent) of the 190 financia...Determining the tax base for each taxable device (15 percent) and deve...

NEW YORK, April 18, 2012 /PRNewswire/ -- Financial executives in the medical device manufacturing industry predict that a new excise tax and the burden of its related compliance costs will have a negative impact on their company bottom lines, according to a survey conducted by KPMG LLP, the audit, tax and advisory firm. Forty percent of respondents said their companies are already contemplating actions such as price increases and cost reductions -- headcount, manufacturing processes, or other means -- to stay competitive.

As part of the Health Care and Education Reconciliation Act of 2010, health care providers who manufacture or import medical devices or equipment for sale in the United States may be subject to a 2.3 percent excise tax. The Internal Revenue Service and the U.S. Department of the Treasury issued proposed regulations pertaining to the tax in February.

In the KPMG survey, almost two-thirds (61 percent) of the 190 financial executives from the medical device manufacturing industry said the excise tax will negatively affect their company's bottom line, and 60 percent believe it will increase their company's tax compliance costs. Fifty-five percent of respondents also expect that it will be difficult for their company to comply with the excise tax, citing confusion over which products will be taxable and challenges in implementing systems for compliance (both 16 percent) as key issues.

Determining the tax base for each taxable device (15 percent) and developing an implementation plan and determining the necessary resources required (13 percent) were also cited as expected compliance hurdles by respondents.

"Manufacturers and importers of medical devices have a great deal of work to do in order to prepare to begin reporting the tax, which is effective for sales on and after the January 1, 2013 effective date and applies to their sales of taxable medical devices in the United States," said Frank Mattei, national tax leader of KPMG's Pharmaceutical and Medical Device practice. "Companies will need to become familiar with the excise tax rules, identify their affected entities and products, and develop the appropriate compliance processes. A 'gap' analysis should be conducted as soon as possible to identify areas that need to be addressed."

The KPMG survey also reveals that, in response to the tax, many medical device industry companies are already considering actions that they believe will help them stay competitive. Twenty-two percent of respondents said their companies would most likely consider increasing the cost of goods sold to the purchaser, while 13 percent said their organizations would most likely consider making cost reductions in areas such as headcount and manufacturing processes. Fifty percent said they were unsure about the actions their company might take.

Thirty-five percent of respondents to the KPMG survey said their company is currently working across several departments to prepare for the implementation of the excise tax regime. Nine percent said steps were being taken to prepare for the implementation within the tax department only, while 30 percent said they were not taking any steps to prepare because they were either still trying to understand the implications or evaluate their options.

"Companies need to work across various functions to prepare for effective compliance, because this is not just a tax issue," said Adam Uttley, a KPMG tax partner focused on accounting methods, credits, and special projects. "Finance and tax departments will need to work with their IT, operations, and regulatory counterparts, while keeping leadership informed of issues that could affect the business.

"Although many may still be hoping for legislative relief, it would be prudent to assume that a first deposit of medical device excise tax will be due by January 29, 2013, and the first quarterly federal excise tax return will be due by April 30, 2013," Uttley added.

The KPMG survey was conducted in March during a KPMG Tax practice-sponsored event focused on the impact of the medical device excise tax.

About KPMG LLP

KPMG LLP, the audit, tax and advisory firm (www.kpmg.com/us), is the U.S. member firm of KPMG International Cooperative ("KPMG International"). KPMG International's member firms have 145,000 people, including more than 8,000 partners, in 152 countries.

(Date:12/8/2016)... 8, 2016 Research and Markets has announced ... Trends - Adhesion Type, Application, Usability - Forecast to 2025" ... , ... Market is poised to grow at a CAGR of around 3.2% ... market is witnessing include advancements in extracellular microelectrode arrays and intracellular ...

(Date:12/8/2016)... TriNetX , the health research network, ... signed a membership agreement to join the network ... cures. The TriNetX network is comprised ... globally, biopharmaceutical companies and contract research organizations (CROs) ... site selection, patient recruitment, and collaborative research across ...

(Date:12/8/2016)... , Dec. 8, 2016 Pennsylvania Physician General ... Drug and Alcohol Programs Gary Tennis ... medications, known as benzodiazepines, developed with the help ... are medications that are frequently prescribed for anxiety ... are used with opioid pain medications, benzodiazepines pose ...

(Date:12/8/2016)... ... December 08, 2016 , ... The Florida ... Undersea and Hyperbaric Medical Society (UHMS), the leading authority in hyperbaric medicine. This ... Only a few hospitals and facilities have earned this distinction. This is the ...

(Date:12/8/2016)... , ... December 08, 2016 , ... ... Chester County, a Property owned by an affiliate of Seavest, has won a ... Penn Medicine Southern Chester County ambulatory care center (ACC) was named “Best New ...

(Date:12/8/2016)... ... 08, 2016 , ... CURE Media Group, the nation’s leading digital and print ... Upstage Lung Cancer in efforts to combat lung cancer, announced CURE Media Group President ... “CURE Media Group is honored to team up with Upstage Lung Cancer in order ...